Several brokerages have updated their recommendations and price targets on shares of Hutchison China MediTech Limited (NASDAQ: HCM) in the last few weeks:

  • 10/19/2017 – Hutchison China MediTech Limited was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 10/16/2017 – Hutchison China MediTech Limited had its price target raised by analysts at Canaccord Genuity to $38.00. They now have a “buy” rating on the stock.
  • 10/13/2017 – Hutchison China MediTech Limited was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 10/5/2017 – Hutchison China MediTech Limited was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 9/14/2017 – Hutchison China MediTech Limited was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 9/6/2017 – Hutchison China MediTech Limited was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.

Shares of Hutchison China MediTech Limited (HCM) traded down 0.97% during midday trading on Monday, reaching $27.50. 23,841 shares of the company’s stock traded hands. The stock has a market cap of $3.34 billion, a price-to-earnings ratio of 259.43 and a beta of -1.89. Hutchison China MediTech Limited has a 52-week low of $11.40 and a 52-week high of $32.03. The stock has a 50 day moving average of $27.75 and a 200-day moving average of $27.75.

Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.

Receive News & Ratings for Hutchison China MediTech Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech Limited and related companies with MarketBeat.com's FREE daily email newsletter.